Now Playing
Opinion|Videos|September 24, 2024
Overview of FINEARTS-HF Trial
Author(s)Javed Butler, MD, MPH, MBA
Javed Butler, MD, MPH, MBA, discusses the FINEARTS-HF trial presented at European Society of Cardiology Congress 2024, highlighting its objective to evaluate finerenone in patients with heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, the randomized design, and results indicating a reduction in worsening HF events compared with placebo.
Advertisement
Video content above is prompted by the following:
- Discuss the data presented at European Society of Cardiology Congress 2024 on the FINEARTS-HF trial evaluating finerenone use among patients with heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF.
- What was the objective of this study?
- How was this study designed, and what methodology was used?
- What results were presented?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
2
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
3
Making the Genetic Models Match the Ancestry of Patient Populations
4
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
5
